论文部分内容阅读
目的观察重组人促红细胞生成素联合放疗对消化道肿瘤的近期疗效和不良反应。方法 62例欲接受放疗的消化道肿瘤患者随机分为治疗组和对照组。治疗组患者在放疗一周前开始接受重组人促红细胞生成素注射液的治疗,每次10 000 IU,每周3次,皮下注射,直至放疗结束。对照组为单纯放疗,两组放疗方式均为三维适形调强放疗,6MV-X线,2 Gy·次-1,每周5次。结果放疗结束后3个月,治疗组、对照组的临床总有效率(RR)分别为96.8%、74.1%(P<0.05);在Ⅰ级和Ⅱ级血红蛋白减少方面,治疗组、对照组分别为0、61.3%和0、35.5%(P<0.05);在Ⅰ级血小板减少方面,治疗组、对照组分别为12.9%和38.1%(P<0.05)。在消化道反应、皮肤损伤和血压升高方面,无显著差异。结论重组人促红细胞生成素注射液联合放疗能提高消化道肿瘤的疗效,减少贫血的发生,值得进一步研究和应用。
Objective To observe the short-term curative effect and adverse reactions of recombinant human erythropoietin combined with radiotherapy on gastrointestinal tumors. Methods Sixty-two patients with gastrointestinal cancer who were to receive radiotherapy were randomly divided into treatment group and control group. Patients in the treatment group began receiving recombinant human erythropoietin injection one week prior to radiotherapy at 10 000 IU each time, three times a week, subcutaneously until the end of radiotherapy. The control group was treated with radiotherapy alone. The radiotherapy methods of the two groups were all three-dimensional conformal intensity-modulated radiation therapy, 6MV-X ray, 2 Gy · times -1, 5 times a week. Results At 3 months after the end of radiotherapy, the total effective rate (RR) of the treatment group and the control group was 96.8% and 74.1% respectively (P <0.05). In the reduction of grade Ⅰ and Ⅱ hemoglobin, the treatment group and the control group (0, 61.3%) and 0 (35.5%) respectively (P <0.05). In Grade I thrombocytopenia, the treatment group and the control group were 12.9% and 38.1% respectively (P <0.05). There was no significant difference in gastrointestinal reactions, skin damage and elevated blood pressure. Conclusion Recombinant human erythropoietin injection combined with radiotherapy can improve the efficacy of gastrointestinal tumors and reduce the occurrence of anemia, which deserves further study and application.